Key result
Ticagrelor did not reduce all-cause death compared with clopidogrel but increased the risk of any bleeding.
Why the study?
Given the high bleeding risk in East Asians, whether East Asian patients with acute coronary syndrome should choose ticagrelor or clopidogrel remains controversial.
Does ticagrelor improve clinical outcomes or increase bleeding compared to clopidogrel in East Asian patients with acute coronary syndrome?
Meta-Analysis (n=3,597)
Does ticagrelor improve clinical outcomes or increase bleeding compared to clopidogrel in East Asian patients with acute coronary syndrome?
In East Asian patients with acute coronary syndrome, ticagrelor increases the risk of bleeding and dyspnea but reduces stent thrombosis compared to clopidogrel, with no difference in all-cause mortality.
Answers are grounded in this paper and cite their sources.
Supports clopidogrel preference in East Asian ACS to minimize bleeding; extends ethnicity-specific evidence on P2Y12 inhibitor trade-offs.
The risk of bleeding is high in East Asians, whether East Asian patients with acute coronary syndrome choose ticagrelor or clopidogrel is still controversial. In this study, PubMed, EMBASE, Cochrane Library database, and other sources were systematically searched. The primary efficacy outcome was all-cause death, the primary safety outcomes were any bleeding, PLATO major bleeding, and fatal bleeding. The secondary outcomes included vascular-cause death, myocardial infarction, stent thrombosis, stroke, and dyspnea. A total of 8 randomized controlled trials with 3597 patients met inclusion criteria. Compared with clopidogrel, ticagrelor had significantly higher incidence of any bleeding [risk ratio (RR), 1.63; 1.33-1.99; P < 0.00001], PLATO major bleeding (RR 1.56; 1.15-2.12; P = 0.004), and dyspnea (RR 2.60; 1.68-4.00; P < 0.00001). However, ticagrelor was associated with a significantly reduced risk of stent thrombosis (RR 0.42; 0.19-0.92; P = 0.03). There was no significant difference in the risk of all-cause death (RR 0.87; 0.64-1.24; P = 0.44), fatal bleeding (RR 2.49; 0.79-7.86; P = 0.12), vascular-cause death (RR 0.88; 1.60-0.30; P = 0.52), myocardial infarction (RR 0.89; 0.65-1.23; P = 0.49), and stroke (RR 0.84; 0.47-1.50; P = 0.56) between the 2 groups. The present findings demonstrated that ticagrelor was associated with a higher risk of any bleeding, PLATO major bleeding, and dyspnea compared with clopidogrel in East Asian patients with acute coronary syndrome. However, it significantly reduced the risk of stent thrombosis. (Registered by PROSPERO, CRD42021255215).
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a meta-analysis in Acute Coronary Syndrome (n=3,597). Ticagrelor vs. Clopidogrel was evaluated on all-cause death (RR 0.87, 95% CI 0.64-1.24, p=0.44). Ticagrelor did not reduce all-cause death compared with clopidogrel but increased the risk of any bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: